Pharming en Infigen

1. [verwijderd] 14 juli 2004 09:00

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Leiden, July 14, 2004. Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) announced
   today that it has reached agreement with Infigen, Inc. (“Infigen”) and obtained broad licenses to the patents of
   Infigen. The licensing agreement enables Pharming to advance commercialization of its product pipeline and
   protein production technology.
   Pharming has obtained worldwide, non-exclusive, royalty-free, non-terminable licenses from Infigen for
   patents on nuclear transfer and associated technologies. The new licensing agreement will replace earlier
   agreements between the companies. The financial terms of the agreement with Infigen were undisclosed and
   has been approved by the Board of Supervisory Directors. Infigen will also relinquish claims to any milestone
   payments for product development as defined under earlier agreements.
   “Pharming has advanced the development of its products by obtaining access to key patents from Infigen as
   well as clearing all milestone payment obligations,” said Dr. Francis Pinto, CEO of Pharming. “In addition, the
   agreement has strengthened our protein production capabilities and allows the Company to pursue
   partnerships in this area.”
   Pharming will continue to strengthen the intellectual property position for its product pipeline and protein
   production technology. Recently, the Company completed an agreement with Probio International Holdings
   Pte Ltd to broaden access to key technology patents and accelerate commercialization of recombinant human
   lactoferrin in Asia.
2. [verwijderd] 14 juli 2004 09:16

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   PERSBERICHT: Pharming in overeenkomst met Infigen
   
   14 juli 2004, 09:12 uur
   (Volledige tekst origineel persbericht)
   
   ---- Pharming and Infigen complete licensing agreement
   
   -- Euronext Amsterdam
   
   Pharming announces:
   
   Leiden, July 14, 2004. Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) announced today that it has reached agreement with Infigen, Inc. ("Infigen") and obtained broad licenses to the patents of Infigen.
   
   The licensing agreement enables Pharming to advance commercialization of its product pipeline and protein production technology. Pharming has obtained worldwide, non-exclusive, royalty-free, non-terminable licenses from Infigen for patents on nuclear transfer and associated technologies. The new licensing agreement will replace earlier agreements between the companies. The financial terms of the agreement with Infigen were undisclosed and has been approved by the Board of Supervisory Directors.
   
   Infigen will also relinquish claims to any milestone payments for product development as defined under earlier agreements. "Pharming has advanced the development of its products by obtaining access to key patents from Infigen as well as clearing all milestone payment obligations," said Dr. Francis Pinto, CEO of Pharming. "In addition, the agreement has strengthened our protein production capabilities and allows the Company to pursue partnerships in this area." Pharming will continue to strengthen the intellectual property position for its product pipeline and protein production technology. Recently, the Company completed an agreement with Probio International Holdings Pte Ltd to broaden access to key technology patents and accelerate commercialization of recombinant human lactoferrin in Asia. Background on Pharming Group N.V. Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company's products include potential treatments for genetic disorders and specialty products for surgical indications. Pharming's lead product for Hereditary Angioedema is in Phase III of clinical development. The advanced technologies of the Company include novel platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, www.pharming.com
   
   This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. End of publication.
   
3. [verwijderd] 14 juli 2004 09:41

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Pharming krijgt licenties op patenten van Infigen
   
   14 juli 2004, 09:37 uur
   AMSTERDAM (Dow Jones)--Biofarmaceutisch bedrijf Pharming heeft licenties gekregen voor het gebruik van de patenten van Infigen, een Amerikaans biotechnologisch bedrijf.
   
   Volgens Pharming-topman Francis Pinto is de overeenkomst belangrijk voor Pharming's ontwikkeling van de productie van mens-eigen eiwitten.
   
   Onder de overeenkomst hoeft Pharming geen royalties en milestone payments te betalen aan Infigen. Financiële details zijn niet bekendgemaakt.
   
   Dow Jones Nieuwsdienst; +31-20-5890270
   
4. MVMR 14 juli 2004 10:38

   auteur info

   • MVMR

     Lid sinds: 03 apr 2002

     Laatste bezoek: 25 feb 2025

   • Aanbevelingen

     Ontvangen: 28

     Gegeven: 0

   •    Aantal posts: 177

   Mooi bericht , zou de positieve berichten stroom op gang aan het komen zijn ? Ze maken nu wel echt progressie , zou de koers toch positief moeten beinvloeden .
   Wie zijn eigenlijk die verdomde verkopers telkens ?